LADENBURG THALM/SH SH Upgrades Turn Therapeutics (NASDAQ:TTRX) to Strong-Buy

Turn Therapeutics (NASDAQ:TTRX) was upgraded by analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a research note on Saturday. D. Boral Capital reissued a “buy” rating and issued a $8.00 price objective on shares of Turn Therapeutics in a report on Tuesday, March 24th. Finally, Weiss Ratings upgraded shares of Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Turn Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Turn Therapeutics Stock Performance

NASDAQ TTRX opened at $10.05 on Monday. The company has a fifty day moving average of $6.47 and a two-hundred day moving average of $4.73. The company has a market capitalization of $299.39 million and a PE ratio of -52.89. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $26.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter.

Institutional Trading of Turn Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Hodges Capital Management Inc. purchased a new position in shares of Turn Therapeutics in the 4th quarter valued at approximately $39,000. LPL Financial LLC purchased a new stake in shares of Turn Therapeutics during the fourth quarter worth approximately $51,000. Tamar Securities LLC purchased a new stake in shares of Turn Therapeutics during the fourth quarter worth approximately $59,000. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter worth $63,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Turn Therapeutics during the fourth quarter worth $68,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.